PP_1170x120_10-25-21

WP1122

WPD Pharmaceuticals partners with CNS on COVID-19 solutions

WPD Pharmaceuticals partners with CNS on COVID-19 solutions

VANCOUVER, British Columbia — WPD Pharmaceuticals announced it has entered into a development agreement with CNS Pharmaceuticals for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2. WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner,

Adheris Health